Overview

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Status:
Completed
Trial end date:
2018-12-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability for the combination therapy of BMS-986205 and Nivolumab in patients with advanced tumors
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Linrodostat
Nivolumab